<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250887</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0526</org_study_id>
    <nct_id>NCT00250887</nct_id>
  </id_info>
  <brief_title>Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research</brief_title>
  <official_title>A Phase II Open Label Study of the Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma&#xD;
      after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy).&#xD;
      Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR). EGFR is&#xD;
      elevated in more than 50% of malignant gliomas. At recurrence, secondary surgery and pre- and&#xD;
      postoperative Gefitinib is offered to patients in good performance status. Clinical outcome&#xD;
      of patients and correlation to translational research will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma (GBM) patients who relapse and are in good performance status, without serious&#xD;
      neurological deficits are offered secondary surgery and participation in the trial. Eligible&#xD;
      patients must have had standard treatment including primary surgery, radiation therapy and at&#xD;
      least a first line chemotherapy. Patients on cytochrome P450 isoenzyme CYP3A4-inducing&#xD;
      antiepileptic drugs (EIAE) are excluded due to ensuing interactions of these drugs with&#xD;
      gefitinib metabolism, reducing systemic availability. After giving written informed consent,&#xD;
      patients receive gefitinib 500 mg daily starting at least 5 days prior to re-operation,&#xD;
      allowing a steady state condition.Treatment continues until tumor progression or occurrence&#xD;
      of intolerable side effects.The specimens collected at surgery will undergo translational&#xD;
      research, aiming to correlate drug accumulation and molecular signatures of GBM samples with&#xD;
      clinical outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>molecular signature of EGFR responsiveness to ZD1839</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitnib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  recurrent glioblastoma&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  reoperation planned&#xD;
&#xD;
          -  fresh frozen sample obtainable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  enzyme inducing antiepileptic drugs&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Hofer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>November 4, 2005</study_first_submitted>
  <study_first_submitted_qc>November 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <last_update_submitted>October 22, 2007</last_update_submitted>
  <last_update_submitted_qc>October 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2007</last_update_posted>
  <keyword>recurrent Glioblastoma, Gefitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

